Linking EudraCT and ClinicalTrials.gov Records Provides Huge Benefit

LONDON, November 15, 2011 /PRNewswire/ --

EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply consensus forecasts of global drug sales, announced today the launch of its new clinical trial intelligence service, EP Clinical Trials^[SM]. By linking EudraCT and ClinicalTrials.gov records, the new service delivers a unique synthesis of clinical trials information that will greatly benefit companies as they manage clinical trial strategies, plan clinical development programs, or seek out investment opportunities.

"Currently 52% (15,900+ trial records) of the EudraCT clinical trial data, originally released in March 2011, has been made public, and we have successfully linked half of this data via NCT-ID reference number to ClinicalTrials.gov records," said Anthony Raeside, Head of Research at EvaluatePharma®,"Our goal is to continue to make the data as meaningful and valuable as possible by indexing, linking, and revealing previously un-recognised synergies between the public clinical trial directories."

By linking the two leading sources of clinical trial records, a few examples of additional information benefit includes:

• Enrolment numbers available for each EU country
• Trials identified for orphan (rare disease) indications
• Standardized technology for investigational drugs disclosed, such as biologic - gene therapy
• Standardized pharmaceutical form such as transdermal patch
• Ability to identify commercial company trials unique to the EudraCT site

EP Clinical Trials^[SM] updated daily, also provides mapped data such as biopharmaceutical company and product information, peak and historical sales, indication, top level deal information, custom data alerts and award winning EP Vantage® commentary and analysis.

About EvaluatePharma Ltd

The research company EvaluatePharma Ltd was the first to supply consensus forecasts of global drug sales and now provides standardized worldwide financial and forecast models with consensus product sales forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A activity. Launched in 2007, EvaluatePharma®Alpha offers a Net Present Value (NPV) valuation service quantifying market events and the impact on product, portfolio and company valuation including the daily online news service EP Vantage®.

EvaluatePharma®, EvaluatePharma®Alpha, and EP Vantage® are services of EvaluatePharma Ltd, headquartered in London, England. In North America, EvaluatePharma Ltd is represented by EvaluatePharma USA, Inc.

http://www.evaluatepharma.com

Media Contacts:

Andrew Beaven
Marketing Director, EvaluatePharma Ltd
T: +44(0)20-7539-1818
E: [email protected]
EvaluatePharma Ltd
11-29 Fashion Street
London
E1 6PX
United Kingdom

Christine Lindgren
EvaluatePharma USA, Inc
T: +1-617-573-9458
E: [email protected]
EvaluatePharma Ltd
15 Broad St.
Suite 401
Boston, MA
02109

SOURCE EvaluatePharma Ltd